LNTH

Lantheus Holdings, Inc. (LNTH) - Form 8-K Summary

Business Context and Reporting Period

Date of Report: August 1, 2026 (Event Date: August 3, 2026)
Company: Lantheus Holdings, Inc.
Event: Entry into a Material Definitive Agreement (Merger Agreement).
Counterparty: Curium US Holdings LLC ("Parent") and Coco Merger Sub Inc. ("Merger Sub").

Lantheus has agreed to be acquired by Curium US Holdings LLC. Upon closing, Lantheus will become a wholly-owned subsidiary of Parent, and its common stock will be delisted from the Nasdaq Global Market.

Key Financial Metrics and Transaction Terms

Merger Consideration:

• Cash: $102.50 per share in cash, without interest.
• Contingent Value Rights (CVRs): One CVR per share, representing the right to receive up to $12.00 in cash upon achievement of specific commercial milestones.

Equity Award Treatment:

• Options: In-the-money options will be cashed out (spread between $102.50 and exercise price) plus CVRs. Underwater options (exercise price < $114.50) receive CVRs only. Options with exercise prices $\ge$ $114.50 are canceled for no consideration.
• RSUs: Outstanding RSUs issued prior to the agreement vest immediately and convert to cash ($102.50/share) plus CVRs. Post-agreement RSUs convert to cash plus CVRs subject to original vesting schedules.
• PSUs: Converted to cash based on earned shares at $102.50/share plus CVRs, subject to time-based vesting.

Transaction Bonuses: A $6.0 million pool approved for certain employees, including $4.0 million for Mary Anne Heino and $500,000 for Daniel M. Niedzwiecki, payable upon closing.

Financing: The transaction is not subject to a financing condition. Parent has secured equity and debt financing commitments.

Material Changes and Milestones

The filing details the structure of the Contingent Value Rights (CVRs) tied to future sales performance of specific franchises. The filing text does not provide current revenue, profit, or cash flow figures for Lantheus, as this is a transaction announcement rather than a periodic financial report.

CVR Milestone Targets (Aggregate Adjusted Sales):

Guidance, Outlook, Risks, and Contingencies

Conditions to Closing:

• Stockholder approval (majority vote).
• Regulatory approvals (including HSR Act waiting period expiration).
• No laws or orders prohibiting the merger.
• No Material Adverse Effect (MAE) on the Company.

Termination Fees:

• Parent to Company: $385 million (general termination) or $100 million (regulatory termination).
• Company to Parent: $228 million.

Outside Date: The merger must be consummated by May 2, 2027, subject to extensions for government shutdowns or regulatory delays, but no later than November 30, 2027.

Risks:

• Failure to achieve CVR milestones due to market conditions, competition, or integration issues.
• Regulatory delays or prohibitions.
• Disruption to business operations and employee retention.
• Uncertainty regarding FDA approvals for new products (e.g., PNT2003, LNTH-2501) and technology transfers (e.g., PYLARIFY TruVu).

Key Facts for Investor Verification

• Total Potential Value: Verify the total consideration per share ($102.50 cash + up to $12.00 CVR) against current market price.
• CVR Probability: Assess the likelihood of achieving the specific sales milestones for Prostate Cancer, Neurology, and DEFINITY franchises by 2030.
• Regulatory Timeline: Monitor the status of HSR Act waiting periods and other antitrust approvals.
• Stockholder Vote: Confirm the date and outcome of the special stockholder meeting required to approve the merger.
• Executive Retention: Note the $6.0 million transaction bonus pool and amended severance agreements for key executives.
• Financing Status: Confirm that Parent's equity and debt financing commitments remain valid and unconditional.